Back to search results
NCT07493967

Short and Long Term Clinical and Patient-Reported Outcomes Associated With Intragastric Balloon Placement in Patients With Nonalcoholic Fatty Liver Disease

Enrolling by Invitation
Not specifiedAges 18+Observational
Methodist Health System
~200 participants
Updated 2026-06-10 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Changes in Weight
Measured over through study completion, up to 18 months
+8 more outcomes measured

Conditions

NAFLD

Explore related trials

Nonalcoholic Fatty Liver Disease

NCT07493967

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Methodist Dallas Medical Center

    Dallas, Texasno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Parvez Mantry · PRINCIPAL_INVESTIGATOR · Methodist Health System

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Obese (defined as a BMI \>30 kg/m2 )
Men and women scheduled to undergo immunoglobulin B placement at Methodist Dallas Medical Center(MDMC)
18 years or older in age
Able to read and understand the study information
Personally signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the study
Subject is willing and able to comply with the scheduled visits, questionnaires, treatment plan, and other study procedures
Pregnant women

What this trial measures

  • Changes in Weightthrough study completion, up to 18 months

    MeasureTotal body weight loss

  • Body Mass Index1 year

    Measure Body Mass Index

  • Waist to hip ratio1 year

    Measure Waist-to-hip ratio

  • Aminotransaminases1 year

    Measure Aminotransaminases

  • Fasting Lipids1 year

    Measure Fasting Lipids

  • Fasting Glucose1 year

    Measure Fasting Glucose

  • HbA1c1 year

    Measure HbA1c

  • Changes in liver histology parameters1year

    Nonalcoholic Fatty Liver Disease activity score- Min: 1.455 ,Max: 0.675

  • Changes in liver histology parameters1 year

    Magnetic resonance electrography- detected liver stiffness/ Fibrosis score-Min:2.5 kilopascals, Max: 3.0 kilopascals